Eurofins strengthens its top leadership team
Brussels/ Nantes, November 6, 2006
Eurofins strengthens its top leadership team
– Dr. Benoit Adelus appointed Executive Vice President –
Brussels/ Nantes, November 6, 2006
Eurofins is pleased to announce the appointment of Dr. Benoit Adelus, 48, as Group Executive Vice President and board member of Eurofins Scientific Service SA as of December 1, 2006 .
“I am delighted that Benoit Adelus shall soon join our top leadership team. His recognised experience in the pharmaceutical and diagnostic industry as well as his leadership qualities will be important assets for the development and the performance of our Group. I am looking forward to work closely together with him.”, said Gilles Martin, CEO of Eurofins.
Up to now Dr. Benoit Adelus was Executive Vice-President of bioMerieux, a leading player in the field of in vitro diagnostics (€ 1 billion turnover, 5,500 employees) . In this function, Benoit Adelus has been responsible for the development of bioMerieux during the last 6 years and for its successful IPO in 2004.
Before that, he had leading positions in the pharmaceutical and biological industry, particularly in the USA and Latin America. Benoit Adelus holds a PhD in veterinary medicine and a diploma of the HEC – ISA business school.
For further information please visit www.eurofins.com or contact:
Investor Relations |
|
|---|---|
|
Dr. Stefan Eckhoff (International Investor Relations) Tél : +32-2-766 16 20 E-mail : ir@eurofins.com |
Hugues Vaussy (Investor Relations France) Tél: +33-(0)2-51 83 21 00 E-mail: irFrance@eurofins.com |
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is a life sciences company providing a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With about 5,000 staff in more than 70 laboratories across 20 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products.
Eurofins is one of the global market leaders in this field. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on Euronext at the Paris (ISIN FR0000038259) and Frankfurt ( WKN 910251) Stock Exchanges ( Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.